January 04, 2018
Agilvax Inc., a biotechnology company that develops targeted cancer immunotherapies and vaccines, announced today that its management team Dr. Federica Pericle (President & CEO) and Les Stewart (COO) will be attending J.P. Morgan Healthcare Conference, Biotech Showcase™ 2018 and RESI San Francisco 2018. Timing and location details are below
- J.P. Morgan Healthcare Conference and will be held January 8-10, 2018 at the Westin St. Francis Hotel 335 Powell St, San Francisco, CA 94102).
- The Biotech Showcase Conference will be held January 8-10, 2018 at the Hilton San Francisco Union Square 333 O'Farrell St, San Francisco, CA 94102).
- RESI San Francisco will be held January 9, 2018 at the Marines’ Memorial Club & Hotel (609 Sutter St, San Francisco, CA 94102).
Agilvax will be available for one-on-one meetings, and gladly welcomes the opportunity to discuss the Company’s immunotherapy and vaccine programs in more detail.
To arrange a one-on-one meeting with Agilvax’s Management Team in San Francisco please kindly contact:
Chief Operating Officer
Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax’s lead product, AX09, is being developed as an immunotherapy for triple-negative breast cancer (TNBC) by targeting cancer stem cells. TNBC has a high frequency of cancer stem cells, which play a critical role in the high rates of recurrence and poor outcomes in TNBC as compared with other forms of breast cancer. The company’s pipeline and drug discovery platform is based on VLPs derived from RNA bacteriophage that have been engineered to display antigens in an ordered geometric pattern, which can be utilized to stimulate robust and specific immune responses to both foreign pathogens and self-antigens. The Company was founded in 2011 and has headquarters in Albuquerque, NM, and offices in El Paso, TX.